US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

First Trust SMID Growth Strength ETF

26.43

+0.17000.65%

Post-market: 26.430.00000.00%16:00 EDT

Volume:1.06K

Turnover:27.89K

Market Cap:26.43M

PE:- -

High:26.45

Open:26.38

Low:26.30

Close:26.26

Loading ...

Overview Company News Filings

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

Scott Power: ASX health stocks fall but… Orthocell nails its US FDA approval

Dimerix to Present at HealthInvest Summit 2025 Highlighting FSGS Clinical Trial Progress

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Press Release: ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Emerging ASX healthcare innovators are ready to impress at HealthInvest 2025

Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Scott Power: ASX health sector falls as market faces gathering storm clouds

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drug

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

The Market Herald

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Health Check: More, please! When record results are not good enough for expectant investors

Middle East healthcare expansion opens doors for ASX stocks

Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FSGS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":26.43,"timestamp":1744920000000,"preClose":26.26,"halted":0,"volume":1057,"hourTrading":{"tag":"盘后","latestPrice":26.43,"preClose":26.43,"latestTime":"16:00 EDT","volume":29,"amount":766.47,"timestamp":1744920002360},"delay":0,"floatShares":1000002,"shares":1000002,"eps":0,"marketStatus":"Market Closed","change":0.17,"latestTime":"04-17 16:00:00 EDT","open":26.38,"high":26.45,"low":26.3,"amount":27889.61,"amplitude":0.005712,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":26.26,"sharesOutstanding":1000002,"nav":25.925333,"aum":26216068.075869,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.43,"preClose":26.43,"latestTime":"16:00 EDT","volume":29,"amount":766.47,"timestamp":1744920002360},"volumeRatio":0.039608486694377276},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":1000002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.039608486694377276,"shares":1000002,"dividePrice":0.7621,"high":26.45,"amplitude":0.005712,"preClose":26.26,"low":26.3,"week52Low":24.39,"pbRate":"--","week52High":32.96,"institutionHeld":0,"latestPrice":26.43,"eps":0,"divideRate":0.028835,"volume":1057,"delay":0,"ttmEps":0,"open":26.38,"prevYearClose":29.7151,"prevWeekClose":26.28,"prevMonthClose":27.34,"prevQuarterClose":27.34,"fiveDayClose":25.96,"twentyDayClose":27.4795,"sixtyDayClose":31.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525894454","title":"ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525894454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525894454?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:57","pubTimestamp":1744113420,"startTime":"0","endTime":"0","summary":"WESTON, Fla., April 08, 2025  -- ZyVersa Therapeutics, Inc. , a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Shareholder Letter addressing the recent PARASOL recommendations expected to shorten drug development time and approval for rare kidney disease, FSGS. The full text of the letter follows.ZyVersa is developing Cholesterol Efflux MediatorVAR 200 for treatment of chronic kidney diseases, initially focusing on FSGS as the lead. Plans for indication expansion include treatments for Alport Syndrome and Diabetic Kidney Disease. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zyversa-therapeutics-ceo-issues-shareholder-115700993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ZVSA","FSGS","BK4007","LENZ"],"gpt_icon":0},{"id":"2524278220","title":"Scott Power: ASX health stocks fall but… Orthocell nails its US FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2524278220","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524278220?lang=en_us&edition=fundamental","pubTime":"2025-04-04 15:46","pubTimestamp":1743752774,"startTime":"0","endTime":"0","summary":"ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets. Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir. HealthInvest 2025 showcased reasons for optimism despite a challenging climate with several key catalysts on horizon","market":"nz","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/04/GettyImages-2202154746-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/04/GettyImages-2202154746-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/scott-power-asx-health-stocks-fall-but-orthocell-nails-its-us-fda-approval/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4084","FSGS","CDC","PW","BK4234"],"gpt_icon":0},{"id":"2524127471","title":"Dimerix to Present at HealthInvest Summit 2025 Highlighting FSGS Clinical Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2524127471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524127471?lang=en_us&edition=fundamental","pubTime":"2025-04-02 06:18","pubTimestamp":1743545919,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) just unveiled an update. Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the HealthInvest S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-to-present-at-healthinvest-summit-2025-highlighting-fsgs-clinical-trial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-to-present-at-healthinvest-summit-2025-highlighting-fsgs-clinical-trial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS","PRGS","SMMF","LU2065732104.USD","BK4211","BK4097"],"gpt_icon":0},{"id":"2524397729","title":"Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524397729","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524397729?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:30","pubTimestamp":1743453000,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS. Data presentations highlight SPARTAN Study results and real-world case studies of FILSPARI across different IgAN patient backgrounds. The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI  in focal segmental glomerulosclerosis , showing that partial and complete proteinuria remission were achieved earlier and more frequently with FILSPARI than irbesartan, and patients that achieved proteinuria remission had low rates of kidney failure.\"We look forward to presenting data exploring FILSPARI’s potential in FSGS where treatment options remain severely limited, as well as data that reinforce the medicine’s clinical benefits in IgAN,\" said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. \"We remain committed to advancing research that supports improved outcomes for people living with rare kidney di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/travere-therapeutics-present-filspari-sparsentan-203000716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","TVTX","NHLD","FSGS"],"gpt_icon":0},{"id":"2523948396","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948396?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease ; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025. Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., March 31, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, highlighted recent progress and reiterated upcoming milestones.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","FSGS","BK4007"],"gpt_icon":0},{"id":"2522050543","title":"Press Release: ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522050543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522050543?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:15","pubTimestamp":1743081300,"startTime":"0","endTime":"0","summary":"-- Phase 2a proof-of concept clinical trial for Cholesterol Efflux. Mediator VAR 200 in patients with diabetic kidney disease . -- Regulatory path for VAR 200's lead indication, focal segmental. glomerulosclerosis , expected to be shorter based on FDA's. alignment with data supporting proteinuria reduction as a clinical. WESTON, Fla., March 27, 2025  -- ZyVersa Therapeutics, Inc. , a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2024, and provides business update.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4604","ZVSA","BK4099","03160","BK4555","BK4139","BK4588","LENZ","TM","BK4585"],"gpt_icon":0},{"id":"2522365044","title":"Emerging ASX healthcare innovators are ready to impress at HealthInvest 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522365044","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522365044?lang=en_us&edition=fundamental","pubTime":"2025-03-27 08:55","pubTimestamp":1743036952,"startTime":"0","endTime":"0","summary":"Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2. Event to highlight some of ASX’s leading up-and-coming health and life sciences companies. EMVision, Microba Life Sciences, Orthocell, Lumos Diagnostics and Dimerix to present at HealthInvest","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/image-1200x678-3-640x362.png","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/image-1200x678-3-640x362.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/emerging-asx-healthcare-innovators-are-ready-to-impress-at-healthinvest-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2520929742","title":"Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2520929742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520929742?lang=en_us&edition=fundamental","pubTime":"2025-03-19 15:57","pubTimestamp":1742371020,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on TVTX stock, giving a Buy rating on March 17. Joseph Schwartz has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-travere-therapeutics-driven-by-snda-submission-and-market-potential-in-fsgs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-travere-therapeutics-driven-by-snda-submission-and-market-potential-in-fsgs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS","LENZ"],"gpt_icon":0},{"id":"2520954173","title":"Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2520954173","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520954173?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:01","pubTimestamp":1742209260,"startTime":"0","endTime":"0","summary":"sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS. If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure. Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring. Additionally, the FDA recently notified the Company that the REMS is no longer necessary to ensure the benefits of FILSPARI outweigh the risk of embryo-fetal toxicity and to minimize the burden on the healthcare delivery system. The Company plans to submit a REMS modification to remove the need to monitor the risk of embryo-fetal toxicity as an amendment to the REMS sNDA currentl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/travere-therapeutics-submits-snda-fda-110100913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVTX","BK4139","FSGS","ETAR","LENZ"],"gpt_icon":0},{"id":"2519883592","title":"Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2519883592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519883592?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:02","pubTimestamp":1741867320,"startTime":"0","endTime":"0","summary":"Award established to recognize leaders in the field of chronic kidney disease advocacyWALTHAM, Mass., March  13, 2025  (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company fou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042162/0/en/Ardelyx-Announces-the-First-Recipients-of-Derek-Forfang-Patient-Advocate-Award.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDX","BK4139","FSGS"],"gpt_icon":0},{"id":"2517278271","title":"Scott Power: ASX health sector falls as market faces gathering storm clouds","url":"https://stock-news.laohu8.com/highlight/detail?id=2517278271","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517278271?lang=en_us&edition=fundamental","pubTime":"2025-03-07 13:15","pubTimestamp":1741324522,"startTime":"0","endTime":"0","summary":"ASX health stocks fell 0.43% over the past week, while the broader market 2.51%. ProMedicus has signed a seven-year, $40 million deal with leading US radiology provider LucidHealth. Opthea falls following release of half-year results as it awaits countdown to topline phase III trial data","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-1687716975-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-1687716975-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/scott-power-asx-health-sector-falls-as-market-faces-gathering-storm-clouds/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4543","BK4084","LU1988902786.USD","HIE","IE0009356076.USD","LU2458330169.SGD","LU0889565833.HKD","LU0056508442.USD","BK4588","TGA","LU0198837287.USD","BK4532","LU0823434740.USD","LU0127658192.USD","LU0823421333.USD","CBD","LU1242518931.SGD","LU1303367103.USD","BK4213","LU1316542783.SGD","LU1923623000.USD","LU1803068979.SGD","IE00BMPRXN33.USD","LU0081259029.USD","BK4585","BK4512","BK4141","BK4529","FSGS","IE00B5949003.HKD","LU2264538146.SGD","BK4566","BK4534","LU1880398554.USD","BK4573","LU2458330243.SGD","BK4605","LU0719512351.SGD","LU1951198990.SGD","LU2250418816.HKD","LU1064131342.USD","LU2054465674.USD","LU2098885051.SGD","BK4575","BK4139","OPT","PW","BK4234","IE0004445239.USD"],"gpt_icon":1},{"id":"2517154768","title":"ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154768","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154768?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"WESTON, Fla., March  06, 2025  (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for tre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038148/0/en/ZyVersa-Therapeutics-Inc-Announces-Pricing-of-2-0-Million-Private-Placement-Priced-At-The-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","FSGS"],"gpt_icon":0},{"id":"2516175506","title":"Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516175506","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516175506?lang=en_us&edition=fundamental","pubTime":"2025-03-04 13:54","pubTimestamp":1741067652,"startTime":"0","endTime":"0","summary":"Dimerix receives upfront payment of 300 million  from FUSO Pharmaceutical Industries under licensing deal. Company recently inked licensing deal with Japanese company for phase III asset in kidney disease DMX-200. Dimerix eligible for further potential development milestones of up to 3.4 billion  plus potential sales milestones and 15–20% royalties on net sales. Special Report: Dimerix has received the initial payment of 300 million  in line with its recently announced licence agreement with Japanese FUSO Pharmaceutical Industries Ltd in Japan for its phase III clinical asset in kidney disease DMX-200. Dimerix  said it had received the initial payment for its licence agreement with FUSO for development and commercialisation of its ACTION3phase III drug candidate DMX-200 to treat focal segmental glomerulosclerosis  kidney disease.Under the deal, FUSO has been granted exclusive rights to commercialise DMX-200 for FSGS in Japan. Dimerix may become eligible to receive:. 400m  on the first ","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/2025-3-4-DXB-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/2025-3-4-DXB-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/dimerix-banks-initial-3-2m-payment-in-japanese-pharma-licensing-deal-for-kidney-drug/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["UAE","ARB","FSGS"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["DMX","BK7508","BK7067","BK7501","DXB.AU","FSGS"],"gpt_icon":0},{"id":"2514325974","title":"Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514325974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514325974?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:05","pubTimestamp":1740744300,"startTime":"0","endTime":"0","summary":"Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI (pegcetacoplan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/28/3034648/0/en/Apellis-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGA","FSGS","BK4213"],"gpt_icon":0},{"id":"2514550806","title":"Ligand Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514550806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514550806?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033694/0/en/Ligand-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLM","FSGS","LU2237438978.USD","BK4201","BK4585","EC","CHMP","LU0053666078.USD","BK4087","BK4588","BK4011","SG9999001077.SGD","BK4548","BK4156"],"gpt_icon":0},{"id":"2514853378","title":"Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853378?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:25","pubTimestamp":1740576300,"startTime":"0","endTime":"0","summary":"-- On track to announce the primary endpoint result from the atacicept. pivotal Phase 3 ORIGIN trial in IgA Nephropathy  in 2Q 2025; BLA. submission to the U.S. FDA for accelerated approval planned in 2H 2025. -- Expanded atacicept clinical development program in multiple autoimmune. planned FDA submission, and potential 2026 commercial launch of atacicept. \"Vera is poised to change the standard of care in autoimmune diseases with atacicept, our investigational therapy, beginning with IgA nephropathy. We are on track to announce the primary endpoint result of the ORIGIN Phase 3 study in the second quarter of this year. We look forward to submitting a Biologics License Application  for this potential best-in-class therapy in the second half of this year. We are grateful to the study investigators and participants for their ongoing and enthusiastic participation in this program,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"In addition, over the past year we have m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445015.USD","BK4139","BKV","LENZ","LU0417517546.SGD","LU2133065610.SGD","BK4550","BK4581","LU0868494708.USD","BK4566","MCD","IE00B7KXQ091.USD","LU0942090050.USD","TACI","BK4534","LU0256863811.USD","LU1244550577.SGD","BK4585","FSGS","BK4209","IE00BJTD4N35.SGD","PMN","IE00BFSS8Q28.SGD","LU1244550494.USD","BK4213","LU1430594728.SGD","IE00BFSS7M15.SGD","LU1244550221.USD","LU0868494617.USD","BK4504","IE00BJJMRX11.SGD","IE00BJTD4V19.USD","VERA","LU1585245621.USD","LU1718418525.SGD","IE00BJJMRY28.SGD","BK4588"],"gpt_icon":0},{"id":"2514364550","title":"Health Check: More, please! When record results are not good enough for expectant investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2514364550","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514364550?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:59","pubTimestamp":1740448741,"startTime":"0","endTime":"0","summary":"Polynovo and Avita Medical are victims of skittish market behaviour. Cyclopharm breathes easier after a good start with US sales. Control Bionics raises $2 million to rev up commercialisation","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1159049945-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1159049945-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-more-please-when-record-results-are-not-good-enough-for-expectant-investors/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2512787194","title":"Middle East healthcare expansion opens doors for ASX stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2512787194","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512787194?lang=en_us&edition=fundamental","pubTime":"2025-02-19 04:40","pubTimestamp":1739911203,"startTime":"0","endTime":"0","summary":"Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies. ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy  device for early detection and prevention of lymphoedema. The Middle East is emerging as a key market for Imricor, which received regulatory approval in Qatar and the Kingdom of Saudi Arabia in 2024","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1462549654-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1462549654-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/middle-east-healthcare-expansion-opens-doors-for-asx-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4533","BK4534","LU1894683264.USD","BK4585","IE0002270589.USD","BK4568","FSGS","SG9999002224.SGD","LU0306806265.USD","LU0321505868.SGD","LU0868494617.USD","BK4588","LU1883839398.USD","IE00B19Z3581.USD","SG9999001176.USD","SG9999011175.SGD","LU0234572021.USD","LU0058720904.USD","LU1066053197.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","BK4007","IE00BBT3K403.USD","LU0321505439.SGD","SG9999013999.USD","BK4550","SG9999002232.USD","UAE","LU0456855351.SGD","LU0225771236.USD","BK4159","BK4599","BIS","LU1894683348.USD","GCC","LU0225284248.USD","LU0985481810.HKD","LU0122379950.USD","IE00B19Z3B42.SGD","LU1066051498.USD","SG9999003800.SGD","LU0289739699.SGD","BK4592","LU0306807586.USD","LU0170899867.USD","LU1023059063.AUD","IE00BLSP4452.SGD","BK4581","CAGR"],"gpt_icon":1},{"id":"2511562672","title":"Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2511562672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511562672?lang=en_us&edition=fundamental","pubTime":"2025-02-13 13:42","pubTimestamp":1739425348,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 11. Analyst Joseph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/travere-therapeutics-strong-buy-rating-driven-by-filsparis-1-billion-market-potential-in-fsgs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/travere-therapeutics-strong-buy-rating-driven-by-filsparis-1-billion-market-potential-in-fsgs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{}}}